Emergent BioSolutions (EBS) Cash from Operations Growth (1y) (2011 - 2026)
Emergent BioSolutions (EBS) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -47.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.27% |
| Mar 31, 2026 | -201.79% |
| Dec 31, 2025 | 197.25% |
| Sep 30, 2025 | -101.50% |
| Jun 30, 2025 | 124.00% |
| Mar 31, 2025 | 82.11% |
| Dec 31, 2024 | -348.91% |
| Sep 30, 2024 | 156.17% |
| Jun 30, 2024 | 141.52% |
| Mar 31, 2024 | 65.98% |
| Dec 31, 2023 | -65.41% |
| Sep 30, 2023 | 181.08% |
| Jun 30, 2023 | -633.33% |
| Mar 31, 2023 | -393.30% |
| Dec 31, 2022 | -71.72% |
| Sep 30, 2022 | -543.11% |
| Jun 30, 2022 | 47.47% |
| Mar 31, 2022 | -831.37% |
| Dec 31, 2021 | 33.37% |
| Sep 30, 2021 | -84.13% |